Bishop MR et al. Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed aggressive B-cell non-Hodgkin lymphoma: Analysis of the Phase III Belinda study. ASH 2021;Abstract LBA-6.
Bishop MR et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med 2021;[Online ahead of print]. Abstract
Caimi PF et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021;22(6):790-800. Abstract
Carlo-Stella C et al. Planned interim analysis of a phase 2 study of loncastuximab tesirine plus ibrutinib in patients with advanced diffuse large B-cell lymphoma (LOTIS-3). ASH 2021;Abstract 54.
Fowler NH et al. Umbralisib, a dual PI3K delta/CK1 epsilon inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol 2021;39(15):1609-18. Abstract
Goldman A et al. Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. J Am Coll Cardiol 2021;78(18):1800-13. Abstract
Hill BT et al. Impact of molecular features of diffuse large B-cell lymphoma on treatment outcomes with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. ASH 2021;Abstract 165.
Hutchings M et al. Glofitamab (glofit) in combination with polatuzumab vedotin (pola): Phase Ib/II preliminary data support manageable safety and encouraging efficacy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). ASH 2021;Abstract 525.
Jacobson C et al. Long-term (4- and 5-year) overall survival in ZUMA-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients with refractory large B-cell lymphoma (LBCL). ASH 2021;Abstract 1764.
Kamdar M et al. Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Results from the randomized phase 3 Transform study. ASH2021;Abstract 91
Kumar A et al. Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma. J Clin Oncol 2021;39(20):2257-65. Abstract
Kuruvilla J et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2021;22(4):512-24. Abstract
Locke FL et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2021;[Online ahead of print]. Abstract
Locke FL et al. Primary analysis of ZUMA‑7: A Phase 3 randomized trial of axicabtagene ciloleucel (axi-cel) versus standard‑of‑care therapy in patients with relapsed/refractory large B-cell lymphoma. ASH 2021;Abstract 2.
Locke FL et al. Real-world outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of large B-cell lymphoma (LBCL): Impact of age and specific organ dysfunction. ASH 2021; Abstract 530.
Matasar MJ et al. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22(5):678-89. Abstract
Morschhauser F et al. Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R/R) follicular lymphoma (FL). ASH2021;Abstract 128.
Neelapu SS et al. Long-term follow-up analysis of ZUMA-5: A phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory indolent non-Hodgkin lymphoma. ASH 2021;Abstract 93.
Roschewski M et al. CAR T-Cell therapy for large B-cell lymphoma – Who, when, how? N Engl J Med 2021;[Online ahead of print]. Abstract
Schuster SJ. Bispecific antibodies for the treatment of lymphomas: Promises and challenges. Hematol Oncol 2021;39(S1):113-6. Abstract
Shouse G et al. Impact of comorbidities on outcomes and toxicity in patients treated with CAR T-cell therapy for diffuse large B-cell lymphoma (DLBCL): A multicenter Rwe study. ASH 2021;Abstract 529.
Straus DJ et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol 2021;8(6):e410-21. Abstract
Thieblemont C et al. Efficacy in tisagenlecelucel in adult patients (pts) with high-risk relasped/refractory follicular lymphoma (r/r FL): Subgroup analysis of the phase II Elara study. ASH 2021;Abstract 131.
Tilly H et al. The POLARIX study: Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma. ASH 2021;Abstract LBA-1.
Tilly H et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2021;[Online ahead of print]. Abstract